Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Mallinckrodt
Express Scripts
Boehringer Ingelheim
McKinsey

Last Updated: January 28, 2022

DrugPatentWatch Database Preview

Investigational Drug Information for Gefapixant


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Gefapixant?

Gefapixant is an investigational drug.

There have been 26 clinical trials for Gefapixant. The most recent clinical trial was a Phase 3 trial, which was initiated on May 10th 2020.

The most common disease conditions in clinical trials are Cough, Fibrosis, and Pulmonary Fibrosis. The leading clinical trial sponsors are Afferent Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., and Celerion.

There are twenty-four US patents protecting this investigational drug and two hundred and three international patents.

Recent Clinical Trials for Gefapixant
TitleSponsorPhase
Efficacy and Safety of Gefapixant (MK-7264) in Adult Participants With Recent Onset Chronic Cough (MK-7264-043)Merck Sharp & Dohme Corp.Phase 3
Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)Merck Sharp & Dohme Corp.Phase 3
A Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-030)-China ExtensionMerck Sharp & Dohme Corp.Phase 3

See all Gefapixant clinical trials

Clinical Trial Summary for Gefapixant

Top disease conditions for Gefapixant
Top clinical trial sponsors for Gefapixant

See all Gefapixant clinical trials

US Patents for Gefapixant

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Gefapixant ⤷  Sign up for a Free Trial Selective P2X3 modulators BELLUS HEALTH COUGH INC. (Laval, Quebec, CA) NEOMED INSTITUTE (Montreal, Quebec, CA) ⤷  Sign up for a Free Trial
Gefapixant ⤷  Sign up for a Free Trial Methods and compositions for treating diseases and conditions Afferent Pharmaceuticals, Inc. (San Mateo, CA) ⤷  Sign up for a Free Trial
Gefapixant ⤷  Sign up for a Free Trial JAK inhibitors containing a 4-membered heterocyclic amide THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) ⤷  Sign up for a Free Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Gefapixant

Drugname Country Document Number Estimated Expiration Related US Patent
Gefapixant Australia AU2018342751 2037-09-18 ⤷  Sign up for a Free Trial
Gefapixant Canada CA3076150 2037-09-18 ⤷  Sign up for a Free Trial
Gefapixant China CN111601601 2037-09-18 ⤷  Sign up for a Free Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Mallinckrodt
Express Scripts
Boehringer Ingelheim
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.